The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing
Open accessPreprint — published as 10.1038/s41586-020-2286-9 · Paper page
Abstract
An outbreak of the novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease, has infected over 290,000 people since the end of 2019, killed over 12,000, and caused worldwide social and economic disruption 1,2 . There are currently no antiviral drugs with proven efficacy nor are there vaccines for its prevention. Unfortunately, the scientific community has little knowledge of the molecular details of SARS-CoV-2 infection. To illuminate this, we cloned, tagged and expressed 26 of the 29 viral proteins in human cells and identified the human proteins physically associated with each using affinity-purification mass spectrometry (AP-MS), which identified 332 high confidence SARS-CoV-2-human protein-protein interactions (PPIs). Among these, we identify 67 druggable human proteins or host factors targeted by 69 existing FDA-approved drugs, drugs in clinical trials and/or preclinical compounds, that we are currently evaluating for efficacy in live SARS-CoV-2 infection assays. The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
Self-citationA novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Cox, J., & Mann, M. (2008) · Nature Biotechnology · doi:10.1038/nbt.1511 · Cited by 14,855
SWISS-MODEL: homology modelling of protein structures and complexes
Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumienny, R., Heer, F. T., de Beer, T. A. P., Rempfer, C., Bordoli, L., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky427 · Cited by 13,067
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688 · cited 2×
“Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).”
BackgroundMethodInhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
A novel coronavirus outbreak of global health concern
Wang, C., Horby, P. W., Hayden, F. G., & Gao, G. F. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30185-9 · Cited by 7,700
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
Cox, J., Hein, M. Y., Luber, C. A., Paron, I., Nagaraj, N., & Mann, M. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.031591 · Cited by 5,180
Research works printed but not linked: 15
- SARS-CoV-2 infected host cell proteomics reveal potential therapy targets. In Review (2020).
- 10.21203/rs.3.rs-17218/v1 · DOI
- 10.1073/pnas.1812588116 · doi:10.1073/pnas.1812588116
- 10.1007/s13238-018-0554-3 · doi:10.1007/s13238-018-0554-3
- 10.1128/AAC.44.4.859-866.2000 · doi:10.1128/aac.44.4.859-866.2000
- 2012, CK2α and CK2α’ subunits differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivatives, Eur. J. Med. Chem, 47, 345, 10.1016/j.ejmech.2011.11.002 · doi:10.1016/j.ejmech.2011.11.002
- 2010, Effect of Inhibiting Histone Deacetylase with Short-Chain Carboxylic Acids and Their Hydroxamic Acid Analogs on Vertebrate Development and Neuronal Chromatin, ACS Med. Chem. Lett, 2, 39
- 10.1016/S0162-3109(00)00193-4 · doi:10.1016/s0162-3109(00)00193-4
- 2017, Diverse heterocyclic scaffolds as dCTP pyrophosphatase 1 inhibitors. Part 2: Pyridone- and pyrimidinone-derived systems, Bioorg. Med. Chem. Lett, 27, 3219, 10.1016/j.bmcl.2017.06.039 · doi:10.1016/j.bmcl.2017.06.039
- Thompson, P. A. et al. Abstract 2698: eFT226, a potent and selective inhibitor of eIF4A, is efficacious in preclinical models of lymphoma. in Experimental and Molecular Therapeutics 2698–2698 (American Association for Cancer Research, 2019). · DOI
- 10.1006/geno.1998.5571 · DOI
- 2017, Ester Prodrugs of IHVR-19029 with Enhanced Oral Exposure and Prevention of Gastrointestinal Glucosidase Interaction, ACS Med. Chem. Lett, 8, 157, 10.1021/acsmedchemlett.6b00332 · DOI
- 10.1124/mol.51.6.1070 · doi:10.1124/mol.51.6.1070
- 10.1101/2020.01.31.929042 · DOI
- 10.1021/jm3012992 · doi:10.1021/jm3012992
Cited by
GraphDTA: predicting drug–target binding affinity with graph neural networks
Nguyen, T., Le, H., Quinn, T. P., Nguyen, T., Le, T. D., & Venkatesh, S. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btaa921 · Cited by 1,220
Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant
Pachetti, M., Marini, B., Benedetti, F., Giudici, F., Mauro, E., Storici, P., Masciovecchio, C., Angeletti, S., Ciccozzi, M., Gallo, R. C., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02344-6 · Cited by 996
Emergence of genomic diversity and recurrent mutations in SARS-CoV-2
van Dorp, L., Acman, M., Richard, D., Shaw, L. P., Ford, C. E., Ormond, L., Owen, C. J., Pang, J., Tan, C. C. S., Boshier, F. A. T., et al. (2020) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2020.104351 · Cited by 774
Sharma, A., Ahmad Farouk, I., & Lal, S. K. (2021) · Viruses · doi:10.3390/v13020202 · Cited by 703
Identification of SARS-CoV-2 inhibitors using lung and colonic organoids
Han, Y., Duan, X., Yang, L., Nilsson-Payant, B. E., Wang, P., Duan, F., Tang, X., Yaron, T. M., Zhang, T., Uhl, S., et al. (2021) · Nature · doi:10.1038/s41586-020-2901-9 · Cited by 530
Romano, M., Ruggiero, A., Squeglia, F., Maga, G., & Berisio, R. (2020) · Cells · doi:10.3390/cells9051267 · Cited by 527
Devaux, C. A., Rolain, J.-M., & Raoult, D. (2020) · Journal of Microbiology, Immunology and Infection · doi:10.1016/j.jmii.2020.04.015 · Cited by 476
Decoding SARS-CoV-2 hijacking of host mitochondria in COVID-19 pathogenesis
Singh, K. K., Chaubey, G., Chen, J. Y., & Suravajhala, P. (2020) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00224.2020 · Cited by 382
Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection
Ramlall, V., Thangaraj, P. M., Meydan, C., Foox, J., Butler, D., Kim, J., May, B., De Freitas, J. K., Glicksberg, B. S., Mason, C. E., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1021-2 · Cited by 351
Peptide-like and small-molecule inhibitors against Covid-19
Pant, S., Singh, M., Ravichandiran, V., Murty, U. S. N., & Srivastava, H. K. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1757510 · Cited by 310
Structural basis of RNA recognition by the SARS-CoV-2 nucleocapsid phosphoprotein
Dinesh, D. C., Chalupska, D., Silhan, J., Koutna, E., Nencka, R., Veverka, V., & Boura, E. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1009100 · Cited by 296
Thomas, T., Stefanoni, D., Dzieciatkowska, M., Issaian, A., Nemkov, T., Hill, R. C., Francis, R. O., Hudson, K. E., Buehler, P. W., Zimring, J. C., et al. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00606 · Cited by 285
SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19
Gusev, E., Sarapultsev, A., Solomatina, L., & Chereshnev, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031716 · Cited by 281
Appelberg, S., Gupta, S., Svensson Akusjärvi, S., Ambikan, A. T., Mikaeloff, F., Saccon, E., Végvári, Á., Benfeitas, R., Sperk, M., Ståhlberg, M., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1799723 · Cited by 277
Rao, S., Lau, A., & So, H.-C. (2020) · Diabetes Care · doi:10.2337/dc20-0643 · Cited by 268
Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion
Zang, R., Case, J. B., Yutuc, E., Ma, X., Shen, S., Gomez Castro, M. F., Liu, Z., Zeng, Q., Zhao, H., Son, J., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012197117 · Cited by 240
Network medicine framework for identifying drug-repurposing opportunities for COVID-19
Morselli Gysi, D., do Valle, Í., Zitnik, M., Ameli, A., Gan, X., Varol, O., Ghiassian, S. D., Patten, J. J., Davey, R. A., Loscalzo, J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025581118 · Cited by 107
“We also found that 76 of the 77 drugs that successfully reduced viral infection do not bind the proteins targeted by SARS-CoV-2, indicating that these network drugs rely on network-based mechanisms that cannot be identified using docking-based strategies.”
BackgroundHost mitochondrial transcriptome response to SARS-CoV-2 in multiple cell models and clinical samples
Miller, B., Silverstein, A., Flores, M., Cao, K., Kumagai, H., Mehta, H. H., Yen, K., Kim, S. J., & Cohen, P. (2021) · Scientific Reports · doi:10.1038/s41598-020-79552-z · Cited by 86
Metadata
- Authors
- Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., O’Meara, M. J., Guo, J. Z., Swaney, D. L., Tummino, T. A., Huettenhain, R., Kaake, R. M., Richards, A. L., Tutuncuoglu, B., Foussard, H., Batra, J., Haas, K., Modak, M., Kim, M., Haas, P., Polacco, B. J., Braberg, H., Fabius, J. M., Eckhardt, M., Soucheray, M., Bennett, M. J., Cakir, M., McGregor, M. J., Li, Q., Naing, Z. Z. C., Zhou, Y., Peng, S., Kirby, I. T., Melnyk, J. E., Chorba, J. S., Lou, K., Dai, S. A., Shen, W., Shi, Y., Zhang, Z., Barrio-Hernandez, I., Memon, D., Hernandez-Armenta, C., Mathy, C. J. P., Perica, T., Pilla, K. B., Ganesan, S. J., Saltzberg, D. J., Ramachandran, R., Liu, X., Rosenthal, S. B., Calviello, L., Venkataramanan, S., Liboy-Lugo, J., Lin, Y., Wankowicz, S. A., Bohn, M., Sharp, P. P., Trenker, R., Young, J. M., Cavero, D. A., Hiatt, J., Roth, T. L., Rathore, U., Subramanian, A., Noack, J., Hubert, M., Roesch, F., Vallet, T., Meyer, B., White, K. M., Miorin, L., Rosenberg, O. S., Verba, K. A., Agard, D., Ott, M., Emerman, M., Ruggero, D., García-Sastre, A., Jura, N., von Zastrow, M., Taunton, J., Ashworth, A., Schwartz, O., Vignuzzi, M., d’Enfert, C., Mukherjee, S., Jacobson, M., Malik, H. S., Fujimori, D. G., Ideker, T., Craik, C. S., Floor, S., Fraser, J. S., Gross, J., Sali, A., Kortemme, T., Beltrao, P., Shokat, K., Shoichet, B. K., & Krogan, N. J.
- Venue
- bioRxiv (Cold Spring Harbor Laboratory)
- Publisher
- openRxiv
- Published
- 2020-03-22
- OpenAlex
- W3012652877
- Cited by
- 395
- References
- 163
- Type
- posted content
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.